SB297 would require the New Mexico Health Care Authority to conduct a regional commercial insurance market assessment every two years beginning July 1, 2026. The assessment would determine the average commercial insurance reimbursement rates for covered Medicaid services in Arizona, Colorado, Utah, Oklahoma, and Texas, and those regional averages would be used as part of a new floor for Medicaid payment rates in New Mexico.
The bill also changes how Medicaid reimbursement is calculated for covered health care services. For each service, the Medicaid rate would be set at the greater of 200% of the Medicare reimbursement rate or the regional average commercial insurance reimbursement rate. In addition, health care entities that receive reimbursement increases under the bill would be required to direct at least 75% of the added revenue toward higher compensation for direct patient-care workers or toward hiring additional direct patient-care staff.
Impact
SB297 would amend the Public Assistance Act by adding a new section governing Medicaid reimbursement methodology and market assessments. It would affect the Health Care Authority, Medicaid providers, and a broad range of licensed health care entities, including hospitals, clinics, hospice agencies, home health agencies, long-term care agencies, pharmacies, and group medical practices. The bill would likely increase Medicaid payment rates for some services and create a statutory requirement that most of the resulting revenue growth be used for workforce compensation or staffing.
Sentiment
Based on the bill text and the absence of recorded committee debate or votes in the provided materials, the overall sentiment appears to be policy-driven and supportive of strengthening health care reimbursement and workforce capacity. The bill is bipartisan in sponsorship, which suggests interest in addressing provider payment adequacy and staffing shortages across the health care system. No formal opposition or recorded controversy is shown in the available context.
Contention
The main potential point of contention is the bill’s cost and its effect on Medicaid spending, since it would require reimbursement rates to rise to the higher of two benchmarks and could increase state expenditures. Another likely issue is the mandate that 75% of increased reimbursement revenue be reserved for direct patient-care compensation or hiring, which may be viewed by providers as restrictive or difficult to administer. The regional market assessment requirement could also raise questions about methodology, comparability across states, and whether commercial insurance rates should be used to set public program payments.